Evofem Bio has launched its Phase 2b/3 clinical trial Amprevence and is accepting enrollees to see how its non-hormonal, on-demand and surfactant-free drug Amphora helps in the prevention of female gonorrhea and urogenital chlamydia.
The trial will enroll nearly 850 women in about 20 American cities. The key goal is to prevent the spread of the Chlamydia trachomatis bacteria; the secondary goal is to prevent the spread of the Neisseria gonorrhoeae infection.
Ampower, the phase 3 study, will look at preventing pregnancy with the Amphora Contraceptive Vaginal Gel with enrollment beginning in the next few weeks.
Data information should be available come early 2019.
Amphora is a vaginal contraceptive and can help prevent certain STDs. It’s been given the status of Qualified Infectious Disease Product for its work in decreasing recurring bacterial vaginosis and preventing urogenital gonorrhea.
Here’s what we've been up to recently.
I was a healthy soldier of just 21 years old. I didn't know why I was so tired all the time, so I just chalked it up to long military days and planning my upcoming wedding. But when the fatigue and slight yellow tinge to my skin caught the attention of one of my superiors, I knew had better get checked out.
If a bill in Kentucky’s General Assembly passes, school districts would be mandated to provide age-suitable sex education to fourth through 12th-grade students. This education would include premarital abstinence and sexually transmitted disease prevention.